All Oncology News

Gene therapy that induces the body to create microRNA-22, a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.

A supplemental new drug application seeking the full approval of erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who progressed during or following at least 1 line of a PD-1/PD-L1 inhibitor in the locally advanced or metastatic setting or within 12 months of neoadjuvant or adjuvant therapy, has been submitted to the FDA.

The European Commission has approved pembrolizumab for use in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score of at least 1.

Sara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast cancer; underscores how Trop-2 and HER2 testing is not necessarily needed for this agent in this population at this time; and shares how ongoing efforts are exploring the utilization of this agent earlier in the treatment course.

The addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy.

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis stimulating agent (ESA) use in adult patients with very low– to intermediate-risk myelodysplastic syndrome (MDS) who may require regular red blood cell (RBC) transfusions.

Funda Meric-Bernstam, MD, discusses the design of the DESTINY-PanTumor02 trial, details the antitumor activity and safety of T-DXd in HER2-expressing solid tumors, and shares additional analyses that will be coming down the pike.

Lyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.

Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages.

Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who may not benefit from standard approaches.

Researchers at Huntsman Cancer Institute identified potential new treatment options for people with endometrial cancer.

The addition of tumor treating fields to paclitaxel did not result in a statistically significant improvement in overall survival vs paclitaxel alone in patients with platinum-resistant ovarian cancer, failing to meet the primary end point of the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial.

Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.

The safety profile of subcutaneous trastuzumab was consistent with the known profile of intravenous administration of the agent and there were no new concerns related to prolonged exposure in patients with HER2-positive metastatic breast cancer.

Maintenance therapy with the PARP inhibitor niraparib prolonged progression-free survival vs placebo in patients with newly diagnosed advanced ovarian cancer.

Circulating tumor DNA status at the time of postoperative minimal residual disease assessment was found to be a prognostic factor for disease-free survival in patients with radically resected stage II to IV colorectal cancer.

The European Medicines Agency has granted orphan drug designation to mitazalimab for use in patients with pancreatic cancer.

Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.

The FDA has granted fast track designation to ALE.C04 for use as a potential therapeutic option in patients with recurrent or metastatic, Claudin-1–positive head and neck squamous cell carcinomas.

Qian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cell therapy in patients with solid tumors.

A Fox Chase Cancer Center researcher has been awarded a $2.5 million grant from the National Institute of General Medical Sciences to investigate RNA structure and stability, work that has implications for cancer, Alzheimer’s, and other degenerative diseases and continues the Fox Chase legacy of basic research.

A supplemental biologics license application seeking the expanded approval of amivantamab-vmjw in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations has been submitted to the FDA.

The combination of pembrolizumab and lenvatinib demonstrated a statistically significant improvement in progression-free survival and objective response rate but failed to improve overall survival compared with pembrolizumab plus placebo as frontline therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

Hans Hammers, MD, PhD, outlines 3 cases of patients with renal cell carcinoma, detailing how each patient’s disease presented and how clinicians proceeded with treatment.

Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.

Sovleplenib provided a statistically significant and clinically meaningful increase in durable response rate over placebo in adult patients with primary immune thrombocytopenia in China.

Pasi A. Jänne, MD, PhD, discusses the advantages of bispecific ADCs that target both HER3 and EGFR; preliminary efficacy and safety data seen with BL-B01D1 in patients with non–small cell lung cancer; and the activity of this agent in patients with head and neck squamous cell carcinoma, small cell lung cancer, and nasopharynx cancer.

Elias Jabbour, MD, outlines additional findings from PhALLCON and their clinical implications for patients with Philadelphia chromosome-positive ALL

An independent data monitoring committee has recommended that the phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia should continue without modifications.